- Acquired by Arcturus Therapeutics Inc., Nov 2017
About
Alcobra Pharmaceuticals is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug, Metadoxine Extended Release (MDX), designed to treat cognitive disorders including attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome. MDX is not a stimulant and works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome. In 2017, six months after Alcobras clinical trial of its main product for treating attention disorders failed, the company announced its intention to merge with Arcturus Therapeutics Inc of San Diego.
Q&A
- What is Alcobra Pharmaceuticals' primary focus?
- Alcobra Pharmaceuticals primarily focuses on the development and commercialization of Metadoxine Extended Release (MDX), a proprietary drug designed to treat cognitive disorders such as attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome.
- When was Alcobra Pharmaceuticals founded?
- Alcobra Pharmaceuticals was founded in February 2008.
- What is the current status of Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals is currently inactive, having been acquired by Arcturus Therapeutics Inc. in November 2017.
- What is the employee count for Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals has 1-10 employees.
- What is the total amount of funding raised by Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals raised a total of $25,000,000 USD.
- What is the mechanism of action for Alcobra Pharmaceuticals' drug, MDX?
- MDX is not a stimulant and works through a different mechanism of action compared to other ADHD treatments.
- What clinical trials has Alcobra Pharmaceuticals completed or is currently conducting for MDX?
- Alcobra Pharmaceuticals has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is also conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome.
- What event led to Alcobra Pharmaceuticals' acquisition by Arcturus Therapeutics Inc.?
- In 2017, six months after a clinical trial of its main product for treating attention disorders failed, Alcobra Pharmaceuticals announced its intention to merge with Arcturus Therapeutics Inc. of San Diego, leading to its acquisition.
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/5219796 |
Identifiers & details
| Founded | 2008-2 |
|---|---|
| Employees (exact) | 3 |
| Status reason | Acquired (Inactive) by Arcturus Therapeutics Inc. on Nov 2017 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Arcturus Therapeutics Inc. 2017-11